Key Points for Decision Makers {#d30e233}
==============================

• Indacaterol is the first once-daily long-acting beta~2~-agonist (LABA) that has been shown to improve lung-function, COPD symptoms, and health-related quality of life (HRQoL) compared to salmeterol and tiotropium.

• The model showed that indacaterol produced cost savings and incremental health benefits over a range of time frames and is therefore a cost-effective alternative to current standard of care for the maintenance treatment of moderate and severe patients with COPD.

• Uncertainty analysis showed that if decision makers are willing to pay £20,000 per QALY gained, there is over 80 % probability that indacaterol is cost-effective compared to salmeterol and tiotropium.

Introduction {#Sec1}
============

Chronic obstructive pulmonary disease (COPD) is a progressive, chronic lung disease that is characterised by airflow limitation. The primary symptoms of breathlessness, excessive sputum production, chronic cough and poor exercise tolerance, result in chronic morbidity and mortality \[[@CR1]\]. Worldwide, by 2020, COPD is projected to rank fifth in burden of disease \[[@CR1]\]. In the UK it is estimated that 3 million people have the disease \[[@CR2]\].

In addition to the health impact, COPD also poses a great financial burden. The direct cost of COPD to the UK healthcare system is estimated to be £810--930 million each year and the broader impact on employers and the UK economy is estimated to be £3.8 billion \[[@CR3]\]. Although the direct costs of COPD in the UK can be estimated, there is little published evidence of the real life healthcare consumption of patients in the different stages of COPD.

COPD is not curable; however there are several effective treatments available. The National Institute for Health and Clinical Excellence (NICE) have published treatment algorithms for the adequate management of patients with COPD in the UK \[[@CR2]\]. The stepwise progression of inhalation therapies recommended by NICE is based on the best available clinical and cost-effectiveness evidence and aims to improve the standard of care for patients with COPD in the UK \[[@CR2]\]. NICE guidelines recommend that patients with moderate to severe COPD initiate maintenance therapy with a long-acting bronchodilator if short-acting bronchodilators are not providing sufficient symptom relief. However there are several long-acting bronchodilators available in the UK. Therefore, healthcare decision makers need to understand which of the available therapies is the most cost-effective from the NHS perspective. Indacaterol is a relatively new once-daily long-acting beta~2~-agonist (LABA) that has been shown to improve lung function, COPD symptoms, and health-related quality of life (HRQoL) endpoints compared with existing monotherapy bronchodilators \[[@CR4]--[@CR6]\].

The use of real-world evidence on the resource use of patients with COPD is valuable in accurately assessing the cost-effectiveness of COPD treatments. The Optimum Patient Care Research Database (OPCRD) \[[@CR7]\] contains anonymised research-quality data from patients attending approximately 300 primary care practices in England and Scotland that subscribe to OPCRD for chronic respiratory review services. These data include longitudinal routine clinical data extracted from practice records of over 20,000 patients with a confirmed diagnosis of COPD.

In this analysis, the effectiveness data from two 6-month clinical trials of indacaterol \[[@CR4], [@CR5]\] (indacaterol 150 and 300 μg doses) have been combined with data from the OPCRD \[[@CR7]\] on healthcare consumption of COPD patients in the different stages of the disease. The clinical effectiveness and resource use data has been applied within an economic model to estimate the longer term expected costs and outcomes associated with indacaterol's use, compared with tiotropium and salmeterol.

Objective {#Sec2}
---------

The aim of this analysis is to use real world evidence of resource use within an economic model to establish the cost-effectiveness profile of indacaterol, the most recent LABA to be launched in the UK, compared with the existing once-daily long-acting muscarinic antagonist (LAMA) tiotropium and the twice-daily LABA salmeterol, in patients with moderate to severe COPD. The analysis took the healthcare payer perspective.

Methods {#Sec3}
=======

Model Structure {#Sec4}
---------------

COPD is a chronic degenerative disease with recurring exacerbations. A Markov model provides a suitable structure to model such a disease. A Markov model comprises discrete health states that describe the status of a patient. Patients stay in one health state for the duration of a model cycle, accumulating the costs and benefits associated with that health state. At the end of a cycle, patients may remain in a state or move to another state, according to defined transition probabilities.

The model was developed as a global model allowing local country adaptations to inform the cost-effectiveness of indacaterol compared with current treatments. A previous publication on the cost-effectiveness of indacaterol in the German setting presents in detail the methodology used to develop the model \[[@CR8]\]. This paper presents the specific methods and results for the UK setting.

This analysis used a Markov model constructed in Microsoft Excel 2007 (Microsoft, Redmond, Washington) with four main health states describing the different COPD severities plus a state for death. For each disease severity state, two further health states were created for patients who experienced a severe (requiring hospitalisation) or non-severe exacerbation (requiring medical management in the community), to give a total of 12 health states plus death, as shown in Fig. [1](#Fig1){ref-type="fig"}. Mirror states were created for the 12 health states to describe the disease progression of patients who discontinued therapy.Fig. 1Model schematic. Reprinted from Respiratory Medicine, Vol 105, David Price, Alastair Gray, Rupert Gale, Yumi Asukai, Laura Mungapen, Adam Lloyd, Lars Peters, Katja Neidhardt, Tobias Gantner, Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD, pp 1635--1647, Copyright (2011), with permission from Elsevier

Model Parameters {#Sec5}
----------------

Cycle lengths were set to 3 months in order to capture initial lung function improvement. Forced Expiratory Volume in 1 second (FEV~1~) was the primary endpoint of the indacaterol studies and most clinical studies show that improvement in trough FEV~1~ is recorded over the first 8--16 weeks of treatment. Trough FEV~1~ versus placebo after 12 weeks of treatment was the primary outcome of the indacaterol studies.

Discounting was set to 3.5 % per annum for both costs and outcomes in line with the NICE guidelines for health technology assessments \[[@CR9]\]. The time horizon in an economic evaluation should cover the full period over which the benefits and costs of an intervention are expected to be accumulated \[[@CR9]\]. Although a lifetime time horizon is recommended in the UK \[[@CR9]\]; in the base case, the analysis was run over a 3-year period. The rationale for conducting the analysis over a shorter period was that the relevant clinical trials for indacaterol extended to 6 months and although it is reasonable to expect patients to take indacaterol for longer time periods given that COPD is a life-long, progressive illness; extrapolation of 6-month data to very long time periods would lead to unacceptable levels of uncertainty in the analysis. Several published economic evaluations in COPD have also used shorter than lifetime time horizons \[[@CR10]--[@CR13]\]. A 3-year duration was considered sufficient to capture costs and benefits, given that many patients are likely to step up or discontinue their maintenance therapy after 3 years \[[@CR14]\]. The results for a 5-year and lifetime time horizon are also presented.

The model population was based on the patients enrolled in the clinical trials who had moderate to severe COPD (classified by post-bronchodilator FEV~1~ between 30 % and 80 % of the normal population), a mean age of 63.6 years, and 67 % were male. The starting distribution in the model reflected the baseline distribution of each trial between health states and is presented in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristics \[[@CR8]\]TrialINHANCEINLIGHT-2Study armsIndacaterol 150 μg\
Indacaterol 300 μg\
Tiotropium 18 μgIndacaterol 150 μg\
Salmeterol 2 × 50 μgLength of study26 weeks26 weeksNumber of subjects (randomised)1683998Mean age, years (standard deviation)63.6 (9.1)63.5 (8.81)Proportion of males (%)62.874.6Duration of COPD, years (standard deviation)6.8 (6.75)6.5 (5.71)Starting disease severity distribution (%) Mild COPD1.41.2 Moderate COPD36.741.3 Severe COPD50.249.4 Very Severe COPD11.698.1

COPD guidelines recommend post-bronchodilator measurement of FEV~1~ for assessment of disease severity \[[@CR1]\], but apart from the screening visit, these were not available from the indacaterol trials. As a consequence, and in line with previous economic analyses \[[@CR11], [@CR15]\], pre-bronchodilator values were used to describe efficacy, utilities and medical resource use for the disease severity health states. The available literature all followed the convention of using pre-bronchodilator values to define these data and since pre-bronchodilator values were used for all comparators the impact on incremental results was minimal. The cut-off points adopted in the clinical trials to define COPD severity were the same as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) \[[@CR1]\], which compares patient FEV~1~ with FEV~1~ for the normal population to ascertain percentage of normal lung function.

Analysis {#Sec6}
--------

A cohort analysis was conducted with the Markov model, based on a population of 1,000 patients. Expected costs and outcomes were used to estimate a total cost, total life-years gained, total severe and non-severe exacerbations and total quality adjusted life-years (QALYs) gained per patient. Incremental cost-effectiveness ratios were reported as cost per QALY gained.

Both one-way and probabilistic sensitivity analyses (PSA) were conducted to test the assumptions of the model and the overall robustness of the results. Tornado diagrams give an indication of the parameters/assumptions which are particularly important contributors to the model's results. Parameters from clinical trial data were varied within the 95 % CIs and parameters for which data on uncertainty were not available were varied by ± 30 %. For the PSA, costs and resource use were varied according to a gamma distribution, utilities by a beta distribution and rate ratios by a log-normal distribution. These distributions were stochastically sampled for 1,000 iterations and the ICER output was recorded. The results of the PSA are shown on a cost-effectiveness plane, where the incremental costs and incremental QALYs for each iteration of the PSA are plotted. The quadrant in which the ICER falls is informative of the cost-effectiveness of the treatment under evaluation.

A threshold analysis was also conducted to assess the impact of using lower prices for tiotropium on the cost-effectiveness results. This is aimed to reflect the situation when branded tiotropium loses exclusivity in the UK.

Clinical Model Inputs {#Sec7}
---------------------

Two key, 6-month trials for indacaterol informed the clinical inputs for the model. The trials were both multi-centre, placebo-controlled, randomised studies with active controls \[[@CR4], [@CR5]\]. The INLIGHT-2 trial was a double-blind study comparing indacaterol (Onbrez Breezhaler^®^, Novartis) 150 μg daily, salmeterol (Serevent^®^, A&H) 50 μg twice daily and placebo \[[@CR5]\]; the INHANCE trial compared indacaterol 150 or 300 μg daily with open-label tiotropium (Spiriva^®^, Boehringer Ingelheim) 18 μg daily \[[@CR4]\]. Each trial provided data on the rate of exacerbations and the improvement in lung function (trough FEV~1~ at week 12 was the primary endpoint). Detailed patient characteristics for these trials have been previously published \[[@CR8]\].

Data from the trials using indacaterol 150 μg dose is presented as the base case as this is the most commonly recommended dose licensed in the UK. Patients are allowed to increase their dose to the 300 μg dose on medical advice, which has been shown to provide additional clinical benefit for patients with severe COPD and therefore the results of the comparison of indacaterol 300 μg versus tiotropium 18 μg have also been presented. Indacaterol 300 μg was not included in the trial versus salmeterol and therefore there are no efficacy results available to inform this comparison in the model.

FEV~1~ Improvement {#Sec8}
------------------

Transition probabilities used in the model were based on transition matrices constructed from individual patient level data, which tracked the movement of patients over the first 12 weeks across different disease states. This allowed the model to fully capture change in disease states rather than using aggregated average improvement in FEV~1~ levels. As discussed above, the primary endpoint of the indacaterol trials was FEV~1~ improvement at week 12 which is a commonly used regulatory time frame cut-off for registration clinical studies. The transition matrices describing the movement of patients over the first 12 weeks in the INHANCE and INLIGHT-2 trials are presented in Table [2](#Tab2){ref-type="table"}. This transition matrix was applied to the first cycle (12 weeks) of the model only, to describe the initial improvement in FEV~1~ after starting therapy. After the first cycle, all patients experience a uniform lung function decline over the model duration (Table [3](#Tab3){ref-type="table"}).Table 2Transition matrix (baseline to 12 weeks) from the INHANCE and INLIGHT-2 trials**From**MildModerateSevereVery Severe**INHANCE150** **μg indacaterolTo** Mild60.00 %8.22 %0.64 %0.00 % Moderate40.00 %84.25 %38.85 %2.63 % Severe0.00%7.53%58.60%63.16% Very Severe0.00%0.00%1.91%34.21%**300** **μg indacaterolTo** Mild62.50%15.07%0.60%0.00% Moderate25.00%78.77%38.32%9.09% Severe12.50%5.48%58.68%63.64% Very Severe0.00%0.68%2.40%27.27%**18** **μg tiotropiumTo** Mild60.00%11.11%0.52%0.00% Moderate40.00%84.26%30.89%2.33% Severe0.00%4.63%64.40%55.81% Very Severe0.00%0.00%4.19%41.86%**INLIGHT-2150** **μg indacaterolTo** Mild66.67%14.29%0.69%0.00% Moderate33.33%75.40%27.59%0.00% Severe0.00%9.52%68.97%57.14% Very Severe0.00%0.79%2.76%42.86%**2** **×** **50** **μg salmeterolTo** Mild75.00%9.57%0.00%0.00% Moderate25.00%80.87%23.08%0.00% Severe0.00%9.57%70.63%53.85% Very Severe0.00%0.00%6.29%46.15%Reprinted from Respiratory Medicine, Vol 105, David Price, Alastair Gray, Rupert Gale, Yumi Asukai, Laura Mungapen, Adam Lloyd, Lars Peters, Katja Neidhardt, Tobias Gantner, Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD, pp 1635--1647, Copyright (2011), with permission from ElsevierTable 3Other model parameters**ParameterValueRange used in SADistributionSource**Discount rate (%)3.5NA^a^NA^a^NICE 2009 \[[@CR9]\]Discontinuation rate (%)1.731.24--4.88BetaAssumption^b^Lung volume decline per year (ml)3028--52NormalTashkin et al. 2008 \[[@CR16]\]^c^Probability of progression to the next COPD severity state0.9Range based on stochastic sampling of lung volume declineNA^a^Calculated based on FEV~1~ decline reported in Tashkin et al. 2008 \[[@CR16]\]Exacerbation rate ratio versus placebo: indacaterol 150 μg (salmeterol analysis)0.750.46--1.21^d^LognormalINHANCE and INLIGHT-2 clinical trialsExacerbation rate ratio versus placebo: salmeterol 150 μg0.630.38--1.05^d^Log normalINHANCE and INLIGHT-2 clinical trialsExacerbation rate ratio versus placebo: indacaterol 150 μg (tiotropium comparison)0.670.46--0.99^d^Log normalINHANCE and INLIGHT-2 clinical trialsExacerbation rate ratio versus placebo: indacaterol 300 μg (tiotropium comparison)0.750.51--1.08^d^Log normalINHANCE and INLIGHT-2 clinical trialsExacerbation rate ratio versus placebo: tiotropium 18 μg0.700.48--1.03^d^Log normalINHANCE and INLIGHT-2 clinical trialsProbability of death due to Mild COPD0^e^0--0^f^BetaRutten-van Molken 2007 \[[@CR12]\]Probability of death due to Moderate COPD0.003^e^0--009^f^BetaRutten-van Molken 2007 \[[@CR12]\]Probability of death due to Severe COPD0.006^e^0--0.018^f^BetaRutten-van Molken 2007 \[[@CR12]\]Probability of death due to Very Severe COPD0.024^e^0--0.053^f^BetaRutten-van Molken 2007 \[[@CR12]\]^a^Variable not included in sensitivity analysis^b^Calculated based on an assumption of an annual discontinuation rate of 7 % that varies between 5 % and 20 %^c^Standard error reported in Tashkin et al. 2008 \[[@CR16]\] was used to estimate the range used in the sensitivity analyses^d^Sensitivity analyses range based on 95 % confidence interval^e^Values from Rutten-van Molken \[[@CR12]\] have been adjusted for the 3-month model cycle length^f^Sensitivity analyses range based on 95 % confidence interval for the rate of exacerbations from the indacaterol clinical trials*COPD* chronic obstructive pulmonary disease, *NA* not available, *SA* sensitivity analyses

Exacerbation Rates {#Sec9}
------------------

The observed exacerbation rates from the placebo control arms of the indacaterol trials were used in the model. Annual rates in the placebo arm were similar across the trials ranging from 0.60 to 0.74 exacerbations per patient per year and these rates set the overall number of exacerbations that occurred in the model. The definition of an exacerbation in the model was based on resource use and differs from that of the clinical trial; severe exacerbations were those requiring hospitalisation and non-severe were those requiring a change in medication and/or contact with a healthcare provider. The probability that an exacerbation would be severe or non-severe in each of the severity stages was based on the clinical trial data. Exacerbations from the placebo arm of the indacaterol trials were pooled and the most recent pre-bronchodilator FEV~1~ value recorded before an exacerbation was used to classify the disease severity status in which the exacerbation took place.

The treatment effect on exacerbation reduction was described as rate ratios and based on the respective studies. Annual rates of exacerbations for the active arms were low in the clinical trials (typically around 0.5 per patient for all treatments) since the study was not enriched to recruit an exacerbating population. All rate ratios were applied to the baseline rate of exacerbations, and therefore rate ratios versus placebo were used. Annual exacerbation rates could not be derived for each treatment by disease severity from the trial data due to the small number of observed events in each study (Table [3](#Tab3){ref-type="table"}).

Other Clinical Inputs {#Sec10}
---------------------

A differential rate of lung function decline was not demonstrated in these two studies and the rate of lung function decline for COPD patients was therefore derived from the UPLIFT \[[@CR16]\] trial, which gave the annual rate of decline in pre-bronchodilator FEV~1~ measurements as 30 ml per year with a standard error of 1 ml; the UPLIFT trial is one of the longest COPD trials conducted recently (Table [3](#Tab3){ref-type="table"}).

Two different mortality rates were utilised in the model in order to fully describe the death rate of a COPD population. The first was a COPD-related mortality and the second was an all-cause mortality rate used to account for deaths from competing causes in the study population. COPD-related mortality was obtained from a published study which gave mortality rates for a COPD patient cohort grouped by disease severity \[[@CR12]\]. While this source accounts for all-cause mortality within this cohort, we have made the assumption that all deaths recorded within this study were COPD-related, since separate measures of COPD-attributable death by disease severity (required to separate the types of death) were not available (Table [3](#Tab3){ref-type="table"}). All-cause mortality was obtained from UK interim life tables for 2008--10 issued by the Office for National Statistics \[[@CR17]\]. In the model, all-cause mortality was not adjusted for COPD-specific deaths due to lack of data.

Economic Model Inputs {#Sec11}
---------------------

Unit costs were obtained from a combination of UK cost sources and costs from the literature. Table [4](#Tab4){ref-type="table"} shows the unit costs for all healthcare products and services used in the model. All costs are expressed as Pounds Sterling (£) for the cost year 2011 and have been inflated to 2011 prices using the Hospital and Community Health Services Index \[[@CR18]\] where necessary. Resource use from the OPCRD \[[@CR7]\] and the literature was validated with a UK clinician with expertise in COPD management.Table 4Cost for health care products and services used in the model**ItemCost (£)Source**Health care services GP visit36.00PSSRU 2011 \[[@CR18]\] Outpatient respiratory specialist visit134.61NHS Reference Costs 2009--10 \[[@CR19]\] Physiotherapist (per hour)34.00PSSRU 2011 \[[@CR18]\] Spirometry51.38NHS Reference Costs 2009--10 \[[@CR19]\] Hospitalisation for COPD exacerbation1693.40NHS Reference Costs 2009--10 \[[@CR19]\] Ambulance transportation to emergency239.42NHS Reference Costs 2009--10 \[[@CR19]\] Pulmonary rehabilitation1017.27Department of Health 2010 \[[@CR3]\] Home oxygen therapy (per day)15.33Oostenbrink et al. 2005 \[[@CR11]\]Drug Indacaterol 150 μg (daily)0.98BNF 62 \[[@CR20]\] Indacaterol 300 μg (daily)0.98BNF 62 \[[@CR20]\] Tiotropium 18 μg (daily)1.06BNF 62 \[[@CR20]\] Salmeterol 2 × 50 μg (daily)0.98BNF 62 \[[@CR20]\] Theophylline (per script)3.43PCA 2011 \[[@CR21]\] Mucolytics (per script)21.85PCA 2011 \[[@CR21]\] Oral corticosteroids (per script)8.79PCA 2011 \[[@CR21]\] SABA (per script)5.98PCA 2011 \[[@CR21]\] ICS (per script)12.12PCA 2011 \[[@CR21]\] SAMA (per script)10.24PCA 2011 \[[@CR21]\] LTRA (per script)31.77PCA 2011 \[[@CR21]\] Influenza vaccination (per administration)14.20Department of Health 2010 \[[@CR3]\] Pneumococcal vaccination (per administration)46.75Department of Health 2010 \[[@CR3]\] Oral corticosteroids, 30 mg^a^ (per day)0.58BNF 62 \[[@CR20]\] Antibiotics^a^ (per day)0.98PCA \[[@CR21]\]; BNF 62 \[[@CR20]\]^a^During exacerbations*BNF* British national formulary, *COPD* chronic obstructive pulmonary disease, *GP* general practitioner, *ICS* inhaled corticosteroids, *LTRA* leukotriene receptor antagonist, *NHS* National Health Service, *PCA* prescription cost analysis, *PSSRU* personal social services research unit, *SABA* short-acting beta-2 agonists, *SAMA* short-acting antimuscarinic bronchodilator

The cost of the different disease states and exacerbations consist of costs accrued in the community and the hospital setting. The cost of community-based care providers were taken from the Personal Social Services Research Unit (PSSRU) \[[@CR18]\] and all hospital services including ambulance, admission costs, professional and lab services were taken from the NHS reference costs 2009--2010 \[[@CR19]\].

Drug prices were obtained from the British National Formulary (BNF) \[[@CR20]\]. For COPD-specific drugs, the recommended dose and package size was used to calculate the cost per day. For the influenza and pneumococcal vaccine, the unit cost to the Department of Health was used, which includes the cost of the vaccine and the GP administration fee \[[@CR3]\]. The OPCRD \[[@CR7]\] reports the number of prescriptions for a specific drug class over a 12-month period. Therefore for these drugs (short-acting beta-2 agonists (SABA), short-acting antimuscarinic bronchodilator (SAMA), inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA), theophylline, mucolytics and oral corticosteroids), the Prescription Cost Analysis dataset 2011 \[[@CR21]\] was used to ascertain the average cost per prescription. The weighted average cost per prescription of the five most common products in each of the drug classes was used.

Home oxygen therapy in the UK is supplied by the Home Oxygen Service which uses specific contractors to supply oxygen in patients' homes \[[@CR22]\]. The cost of this service was not readily available and therefore the cost per day of oxygen therapy reported in a published cost-effectiveness analysis \[[@CR11]\] has been inflated and converted from local currency and used in the model. NICE clinical guidelines recommend that all very severe COPD patients are assessed for home oxygen \[[@CR2]\]. It is reported that approximately 40 % of very severe COPD patients should be on home oxygen, however currently it is believed that only half of those who require home oxygen receive it \[[@CR3]\]. In the base case, it is assumed that all patients who require home oxygen receive it (i.e. 40 % of very severe COPD patients \[[@CR3]\] and 5 % of severe COPD patients).

There was limited evidence on the cost of delivering pulmonary rehabilitation to COPD patients in the UK. The cost estimate used in the model was taken from a report by the Department of Health on the development of a national strategy for COPD services \[[@CR3]\].

This analysis used real-life resource use from the OPCRD \[[@CR7]\]. Of the over 28,000 COPD subjects in the database, 20,001 patients had a confirmed diagnosis with an FEV~1~/Forced Vital Capacity (FVC) ratio \< 0.7. Using the 20,001 subjects, the average use of concomitant medications (SABA, SAMA, ICS, LTRA, theophylline, mucolytics and oral corticosteroids), pulmonary rehabilitation and GP consultations related to COPD were calculated for each of the COPD GOLD stages. Resource use data not available in the OPCRD \[[@CR7]\] (respiratory specialist visits, and spirometry) were taken from the literature \[[@CR11]\]. Table [5](#Tab5){ref-type="table"} shows the resource utilization rates for the health states that were applied in the model.Table 5Resource utilisation for model health states**Annual resource utilisation for maintenanceMildRange used in SAModerateRange used in SASevereRange used in SAVery SevereRange used in SADistributionSource**Influenza vaccination0.730.53--0.93^a^0.730.53--0.93^a^0.730.53--0.93^a^0.730.53--0.93^a^BetaDepartment of Health/HPA 2011 \[[@CR32]\]Pneumococcal vaccination0.690.49--0.89^a^0.690.49--0.89^a^0.690.49--0.89^a^0.690.49--0.89^a^BetaDepartment of Health \[[@CR3]\]Theophylline (number of scripts)0.260.18--0.34^b^0.320.22--0.41^b^0.730.51--0.95^b^1.631.14--2.11^b^GammaOPCRD 2012 \[[@CR7]\]Mucolytics (number of scripts)0.350.24--0.45^b^0.400.28--0.52^b^0.800.56--1.052.051.43--2.66GammaOPCRD 2012 \[[@CR7]\]Oral corticosteroids (number of scripts)0.880.61--1.14^b^0.960.67--1.25^b^1.701.19--2.212.701.89--3.52^b^GammaOPCRD 2012 \[[@CR7]\]; clinical opinionSABA (number of scripts)3.742.62--4.86^b^4.653.25--6.04^b^6.874.81--8.93^b^9.786.85--12.71^b^GammaOPCRD 2012 \[[@CR7]\]ICS (number of scripts)0.890.62--1.16^b^0.810.57--1.05^b^0.710.50--0.93^b^0.620.44--0.81^b^GammaOPCRD 2012 \[[@CR7]\]SAMA (number of scripts)0.590.41--0.77^b^0.650.46--0.85^b^0.910.64--1.19^b^1.190.84--1.55^b^GammaOPCRD 2012 \[[@CR7]\]LTRA (number of scripts)0.000^b^0.000^b^0.370.26--0.48^b^0.000^b^GammaOPCRD 2012 \[[@CR7]\]Pulmonary rehabilitation0.020.02--0.03^b^0.030.02--0.04^b^0.060.04--0.08^b^0.090.06--0.12^b^OPCRD 2012 \[[@CR7]\]Home oxygen therapy (proportion of patients)0.000^b^0.000^b^0.050.04--0.07^b^0.400.28--0.52^b^BetaClinical opinion; Department of Health \[[@CR3]\]GP visits15.0510.54--19.57^b^15.7611.03--20.48^b^16.2011.34--21.05^b^16.1611.31--21.01^b^GammaOPCRD 2012 \[[@CR7]\]Outpatient respiratory specialist visit00^b^00^b^21.40--2.60^b^42.8--5.2^b^GammaOostenbrink et al. 2005 \[[@CR11]\]Spirometry (number of tests)10.7--1.3^b^21.4--2.6^b^21.4--2.6^b^42.8--5.2^b^GammaOostenbrink et al. 2005 \[[@CR11]\]Resource utilisation was validated by a UK clinician^a^Sensitivity analyses range varied by ± 20 % based on assumption; ^b^Sensitivity analyses range varied by ± 30 % based on assumption*COPD* chronic obstructive pulmonary disease, *GP* general practitioner, *HPA* health protection agency, *ICS* inhaled corticosteroids, *LTRA* leukotriene receptor antagonist, *OPCRD* optimum patient care research database, *SA* sensitivity analyses, *SABA* short acting beta-2 agonists, *SAMA* short acting antimuscarinic bronchodilator

Resource use associated with exacerbations was unavailable from the OPCRD \[[@CR7]\] and therefore are based on assumptions that have been validated by a clinician. For a non-severe exacerbation, it was assumed that all patients visited the GP once, and 50 % took antibiotics and oral corticosteroids for 7 days and 50 % took these therapies for 14 days (an average of 10.5 days for all patients). For severe exacerbations it was assumed that 70 % of patients arrived at hospital in an ambulance before they were admitted. In addition it was assumed that patients took antibiotics and oral corticosteroids for 10.5 days (Table [6](#Tab6){ref-type="table"}).Table 6Resource utilisation for exacerbations**Resource utilisation per episodeNon-severe exacerbationRange used in SASevere exacerbationRange used in SADistributionSource**Oral corticosteroids (days of treatment)10.507--14^a^10.507--14^a^GammaClinical opinionAntibiotics (days of treatment)10.57--14^a^10.57--14^a^GammaClinical opinionGP visits10.7--1.3^a^00GammaClinical opinionHospitalization001NA^b^NAAssumptionAmbulance transportation to emergency (proportion of patients)000.70.49--0.91^c^BetaClinical opinion^a^Clinical opinion suggests drug taken for between 7--14 days^b^Not included in the sensitivity analyses as a hospital admission is part of the definition of a severe exacerbation^c^Sensitivity analyses range varied by ± 30 % based on assumption*GP* general practitioner, *NA* not available, *SA* sensitivity analyses

Utility Inputs {#Sec12}
--------------

European Quality of Life -- five dimensions (EQ-5D) is a standardised questionnaire used to measure HRQoL and allows the calculation of a utility value for a specific health state \[[@CR23]\]. EQ-5D data were collected in the three indacaterol phase III clinical trials at the start of the studies, at week 12 (primary endpoint) and at week 26 (end of the studies) \[[@CR24]\]. In the indacaterol trials, whenever an EQ-5D questionnaire was completed at a time for which a pre-bronchodilator FEV~1~ value was available, the EQ-5D score was labelled as describing the corresponding disease severity health state. Over 11,000 EQ-5D questionnaires were pooled and analysed to describe the HRQoL for the COPD disease severity health states. Although the EQ-5D data were collected from subjects across 21 different countries, the UK National Health Survey preference weights was used to value the utility score \[[@CR24], [@CR25]\].

No utility data were available from the trials to describe an exacerbation and therefore values from a published study which measured the disutility associated with an exacerbation was used \[[@CR26]\]. This study recruited participants from the general population in the Netherlands and aimed to include subjects who represented the Dutch population in terms of age, sex and education level \[[@CR26]\]. Participants were asked to value several COPD health profiles using both the visual analogue scale and the time trade-off method \[[@CR26]\]. The utility decrements for COPD exacerbations reported using the time trade-off methodology was used in the model (Table [7](#Tab7){ref-type="table"}).Table 7Utility values**Utility valueRange used in SADistributionSourceStable health state**Mild0.820.8--0.84BetaPooled indacaterol clinical trials \[[@CR24]\]Moderate0.800.79--0.81BetaPooled indacaterol clinical trials \[[@CR24]\]Severe0.770.77--0.78BetaPooled indacaterol clinical trials \[[@CR24]\]Very Severe0.740.73--0.76BetaPooled indacaterol clinical trials \[[@CR24]\]**ExacerbationsUtility decrementSource**Non-severe exacerbation0.010--0.024BetaRutten-van Molken et al. 2009 \[[@CR26]\]Severe exacerbation0.0420.024--0.060BetaRutten-van Molken et al. 2009 \[[@CR26]\]*SA* sensitivity analyses

Results {#Sec13}
=======

Cost-Utility Analysis {#Sec14}
---------------------

The deterministic cost-effectiveness results for the comparison of indacaterol 150 μg daily to tiotropium 18 μg daily and salmeterol 50 μg twice daily over a 3-year time horizon are summarized in Table [8](#Tab8){ref-type="table"}. In comparison with salmeterol and tiotropium, indacaterol results in a per-patient cost savings of approximately £110 and £248 respectively and produces improved outcomes. This results in indacaterol being in a position of dominance against both comparators.Table 8Cost-effectiveness results for indacaterol for a 3-year time horizon**Indacaterol 150** **μgTiotropium 18** **μgDifference**Total costs£4534£4781−£248Total QALYs2.1582.1500.008ICERDominant^a^**Indacaterol 150** **μgSalmeterol 2** **×** **50** **μgDifference**Total costs£4583£4692−£110Total QALYs2.1582.1490.008ICERDominant^a^**Indacaterol 300** **μgTiotropium 18** **μgDifference**Total costs£4501£4760−£259Total QALYs2.1622.1510.011ICERDominant^aa^Dominant = less cost, better outcomes*ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life-years

The INHANCE trial included a comparison of indacaterol 300 μg daily against tiotropium 18 μg daily. This comparison also results in lower costs and improved benefits for the indacaterol treatment group, also resulting in a position of dominance (Table [8](#Tab8){ref-type="table"}). The cost-utility results for the 5-year and lifetime time horizons are presented in Table [9](#Tab9){ref-type="table"}.Table 9Cost-effectiveness results for indacaterol using a 5-year and lifetime time horizon**5**-**year time horizonIndacaterol 150** **μgTiotropium 18** **μgDifference**Total costs£7102£7457−£355Total QALYs3.3573.3400.016ICERDominant^a^**Indacaterol 150** **μgSalmeterol 50** **μg twice dailyDifference**Total costs£7174£7330−£155Total QALYs3.3573.3390.018ICERDominant^a^**Indacaterol 300** **μgTiotropium 18** **μgDifference**Total costs£7054£7427−£374Total QALYs3.3673.3440.023ICERDominant^a^**Lifetime time horizon (20** **years)Indacaterol 150** **μgTiotropium 18** **μgDifference**Total costs£17189£17720−£532Total QALYs7.8737.7950.078ICERDominant^a^**Indacaterol 150** **μgSalmeterol 50** **μg twice dailyDifference**Total costs£17270£17485−£215Total QALYs7.8667.7730.093ICERDominant^a^**Indacaterol 300** **μgTiotropium 18** **μgDifference**Total costs£17,104£17,682−£579Total QALYs7.9297.8100.119ICERDominant^aa^Dominant = less cost, better outcomes*ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life-years

Other Health Outcomes {#Sec15}
---------------------

In addition to HRQoL, the model also estimated the amount of exacerbations and mortality over the time horizon. Over the 3-year time horizon, approximately 10 % of patients receiving indacaterol had died compared with 10.8 % of patients receiving salmeterol and 10.4 % receiving tiotropium. Over the same time frame, indacaterol patients experienced 1.21 non-severe exacerbations and 0.09 severe exacerbations. In comparison, the salmeterol and tiotropium patients experienced 1.14 and 1.30 non-severe exacerbations respectively and 0.09 severe exacerbations.

Sensitivity Analyses {#Sec16}
--------------------

The results of one-way sensitivity analyses for indacaterol versus salmeterol and tiotropium are summarised in a tornado diagram in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} respectively. In both comparisons with salmeterol and tiotropium, indacaterol was dominant, and therefore a tornado diagram will show negative ICERs which are not interpretable. However one-way analyses were conducted in both cases and plotted on a tornado diagram to ascertain the parameters with the most significant impact on the results.Fig. 2Tornado diagram (indacaterol 150 μg versus salmeterol 2 × 50 μg). \^Low value for the mortality rate was 0 % for all severities. The high value was Moderate COPD 0.89 %, Severe COPD 1.78 % and Very Severe COPD 5.34 %. \*Low value for the utility was Mild COPD 0.80, Moderate COPD 0.79, Severe COPD 0.77 and Very Severe COPD 0.73. The high value for the utility was Mild COPD 0.84, Moderate COPD 0.81, Severe COPD 0.78 and Very Severe COPD 0.76. *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *FEV1* forced expiratory volume in 1 second, *M* moderate, *NS* non-severe, *S* severe, *VS* very severeFig. 3Tornado diagram (indacaterol 150 μg versus tiotropium 18 μg). \^Low value for the mortality rate was 0 % for all severities. The high value was Moderate COPD 0.89 %, Severe COPD 1.78 % and Very Severe COPD 5.34 %. \*Low value for the utility was Mild COPD 0.80, Moderate COPD 0.79, Severe COPD 0.77 and Very Severe COPD 0.73. The high value for the utility was Mild COPD 0.84, Moderate COPD 0.81, Severe COPD 0.78 and Very Severe COPD 0.76. *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *FEV1* forced expiratory volume in 1 second, *M* moderate, *NS* non-severe, *S* severe, *VS* very severe

In both comparisons, the variable producing the highest ICER was the proportion of the cohort in the different stages of the disease. The base-case model cohort consisted of the proportion of subjects in the different stages of COPD as observed in the clinical trial. When it was assumed that all subjects started in the Moderate COPD stage, the ICER was approximately £72,894 and £3,537 per QALY in the comparison against salmeterol and tiotropium respectively. The lung function benefit in the model has the impact of indirectly slowing down the progression of disease, and the cost savings in the model are as a result of slowing the progression of patients to the Severe and Very Severe COPD stages. However, when all subjects start with Moderate COPD and the model is run for a 3-year time horizon, there is insufficient time to realise the full benefits of slowing the progression of the disease to the more severe COPD states.

The other variable that had a notable impact on the results for both comparisons was the mortality rate associated with the Very Severe COPD health state. Slowing the progression to more severe COPD states also has the benefit of keeping subjects in health states with lower mortality rates. Mortality rates for all disease severity states were tested; however, indacaterol remained the dominant treatment.

The PSA shows that over 72 % of iterations in the salmeterol comparison and over 89 % of iterations in the tiotropium comparison appear in the south east quadrant of the cost-effectiveness plane, indicating that indacaterol was dominant in the majority of PSA iterations in both comparisons (Fig. [4](#Fig4){ref-type="fig"}). A cost-effectiveness acceptability curve (CEAC) (Fig. [5](#Fig5){ref-type="fig"}) shows the probability that an intervention is cost-effective at different thresholds for the willingness to pay for a QALY gained. At a willingness-to-pay threshold of £20,000 per QALY gain, the probability that indacaterol is cost-effective is approximately 82 % and 84 % for the comparisons with salmeterol and tiotropium respectively. The CEAC curve plateaus at approximately 89 % for both comparisons. This is due to the small percentage of PSA iterations that resulted in inferior or dominated results (values in the northwest and southwest quadrants in Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Cost-effectiveness planeFig. 5Cost-effectiveness acceptability curve

The threshold analysis consisted of running the analysis for various percentage reductions on the price of tiotropium after 1 year of the model time horizon. The results showed that for up to a 41 % reduction on the price of branded tiotropium (a daily cost of £0.63 compared with £1.06 in the base case), indacaterol remained the dominant strategy. In over 43 % of the PSA iterations, indacaterol was the dominant strategy (data not shown) and at a willingness-to-pay threshold of £20,000 per QALY gain, there was over 76 % probability that indacaterol is cost-effective (data not shown).

Model Validation {#Sec17}
----------------

The model results were compared with other studies and reviewed by an external health economist to validate its structure. Comparisons of life expectancy with several epidemiology sources for COPD patients \[[@CR27], [@CR28]\] as well as statistics from the US Center of Disease Control and Prevention (CDC) showed that mortality rates in the model were similar. Model inputs and outputs were also compared with existing economic evaluations \[[@CR12], [@CR29]\] and found to be comparable.

Discussion {#Sec18}
==========

Clinical trials have shown that compared with both salmeterol and tiotropium, indacaterol results in greater lung volume improvements after 12 weeks of treatment \[[@CR4], [@CR5]\]. This clinical benefit allowed patients within the model to improve their disease severity classification in the first model cycle. This results in a larger proportion of patients in the indacaterol treatment arm initially improving to a milder disease state and therefore enjoying a better quality of life, lower costs and a slower progression to more severe states compared with those that don't benefit from the initial change to a milder disease state. This benefit was the key driver to producing ICERs which were dominant against both comparators.

The INHANCE trial included a comparison of indacaterol 300 μg daily against tiotropium 18 μg daily. The increased dosage of indacaterol has been shown to produce increased benefits, and can be prescribed for patients with severe COPD. In addition to the increased benefits, in the UK indacaterol 300 μg daily has the same price as indacaterol 150 μg daily, resulting in the increased dose also being dominant against tiotropium.

The indacaterol studies did not recruit patients on the basis of exacerbations and therefore there was a low rate of exacerbations across these trials. The trials showed a similar positive trend between all active treatments in comparison with placebo in preventing exacerbations however, the rate ratios from the trial which directly compared indacaterol with other bronchodilators all contain 1.0 in the confidence interval, thus making the results statistically non-significant. The model output for exacerbations resulted in patients in the tiotropium treatment arm having slightly more, and patients in the salmeterol arm having slightly fewer exacerbations than those in the indacaterol treatment group.

The one-way sensitivity analyses highlighted the importance of the input values for mortality rates on the results. Although no mortality benefit was assumed with any treatment, the differential mortality rates by disease severity combined with the improvement in lung function, which indirectly slowed progression to more severe COPD states which have higher mortality rates, also bestowed an indirect mortality benefit.

The composition of the model population also had a significant impact on the results. When it was assumed that the model consisted of only moderate COPD patients, the ICER increased. As a result of having a 100 % moderate starting population, fewer subjects improve to a less severe disease state compared with patients starting in the severe disease state.

Another determinant of cost-effectiveness was the time horizon of the model. Extending the time horizon from 3 years to longer timeframes reduces the ICER. This is because the model assumed that the FEV~1~ benefit incurred at the beginning of treatment will not be lost over the course of the lifetime, that is, the slope of lines describing lung function decline will remain parallel between treatment groups until death. Other studies have shown that the initial FEV~1~ improvement can last up to 3 years \[[@CR30]\] however the maintenance of benefit has not been demonstrated in longer term studies. This assumption resulted in indacaterol patients remaining in milder disease states for longer and benefiting from the indirect mortality benefit over an extended timeframe.

It is expected that when branded tiotropium loses exclusivity in the UK, the cost of tiotropium will reduce, however the extent of the price reduction is unknown. The threshold analysis showed that if the cost of tiotropium was discounted by up to 41 % after 1 year of the model time horizon, indacaterol would remain the dominant strategy.

The majority of the resource utilisation data for the different health states in the model were taken from real world evidence of resource consumption by COPD patients in the UK. The use of the OPCRD \[[@CR7]\] ensures the model reflects current clinical practice without which the results would be based on assumptions and estimations.

These results indicate that all doses of indacaterol can produce better outcomes at a lower cost to the healthcare system compared with current treatments. Although there was no clinical data to support a comparison of indacaterol 300 μg with salmeterol, given that the daily cost of both indacaterol formulations are the same; the cost-effectiveness results are likely to be similar or better than the comparison with indacaterol 150 μg. In the context of currently available treatments for the maintenance therapy of COPD, indacaterol provided a cost-effective alternative to the current standard of care.

Limitations {#Sec19}
-----------

Limitations can arise from the model structure, model assumptions and data inputs. A limitation of Markov models is that it is not possible to record the history of a patient and therefore it cannot keep track of patients who discontinue treatment. Those who discontinue no longer benefit from the improvement in lung function from the active therapy. The trial data showed that discontinuation rates were similar among all three interventions, justifying the assumption in the model of equal discontinuation rates for all active treatments.

The key model assumption that lung function improvement changes COPD disease severity and therefore results in an implicit mortality benefit is a limitation of the model, as the clinical trials do not demonstrate this as an endpoint. However previous COPD models have set precedence for modelling lung function improvement in this way \[[@CR11], [@CR12], [@CR29]\]. In addition, there is little evidence illustrating the relationship between change in lung function and change in health status \[[@CR1]\]. In this model, improved lung function is assumed to lead to a change in health status as a result of a change in COPD disease severity.

Model inputs were taken from several sources including clinical trials, published and grey literature, and a clinical practice database. The incorporation of several sources results in the use of data derived from different and possibly inconsistent methodologies. However the impact on the ICER results were minimised by using a consistent source for the equivalent model input across all treatments arms.

There were some limitations with the use of the OPCRD database \[[@CR7]\]. The OPCRD only captures medical data recorded in GP practices. Therefore any resource use prescribed by specialists was incompletely recorded. Since the more severe COPD patients are more likely to be treated by a specialist, the cost of managing the more severe health states may be underestimated.

As with most RCTs, patients with unstable co-morbidities were excluded from the study. Therefore the generalisability of these results is limited to the patient population of the indacaterol clinical trials. There is some evidence that patients with COPD also suffer from several co-morbidities and patients with more severe COPD may also have more numerous and severe co-morbid conditions \[[@CR1], [@CR31]\]. Although this is not reflective of real world evidence, the inclusion/exclusion criteria applied equally to all treatment arms and therefore should not bias the ICER. However a greater understanding of the impact of co-morbidities in the COPD population may lead to a more accurate estimate.

The clinical data used in this model were derived from trials of 6-month duration and therefore a limitation of the analysis is the uncertainty introduced in extrapolating these data to the 3-year base-case period and the longer time horizons assessed. Real world evidence or analyses based on trials with a longer duration are recommended to validate the model's longer-term projections in the future.

Clinical studies of 6-month durations may also not sufficiently capture seasonal variation with regard to exacerbation rates and therefore a model based on these may not be generalisable to real-world exacerbation rates. However recruitment in the studies was spread out such that the total observation period spanned more than 6 months and was conducted in both the northern and southern hemispheres.

These studies also had a very low overall rate of exacerbations observed and are not the ideal data source for exacerbations, but are the best data to describe the exacerbation benefits of indacaterol currently available. More clinical trial data addressing the exacerbation benefit is expected to be reported later in 2013. To test the uncertainty of the clinical evidence, these parameters are included in the one-way and probabilistic sensitivity analyses. Given the very low and very similar rates of exacerbation between the comparators, disabling the exacerbation parameters had very little impact on the results.

Conclusion {#Sec20}
==========

The current cost-utility analysis combined real-world evidence with clinical trial data to compare indacaterol with tiotropium and salmeterol for use as maintenance treatment for COPD in the UK. The analysis demonstrated that indacaterol dominates in both comparisons and is likely to remain cost-effective under a range of assumptions. The comparison of indacaterol 300 μg with tiotropium shows that the higher-dose form is still well positioned to demonstrate cost-effectiveness. As a potential first-line maintenance treatment for moderate and severe COPD patients, indacaterol is a cost-effective alternative to current standard of care.
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